Jardiance Cost in Tennessee 2026: Prices, Medicaid, Insurance, and Compounded Options

What Is Jardiance and Why Does Its Cost Matter in Tennessee?

Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes (T2D) glycemic control, heart failure (HF) with reduced or preserved ejection fraction, and chronic kidney disease (CKD) risk reduction. The FDA label for Jardiance details each approved indication and dosing schedule.

Cost matters here because Tennessee has one of the highest rates of diabetes in the country. The CDC reported that 13.4% of Tennessee adults had diagnosed diabetes in 2022, above the national average of 11.6%. CDC Diabetes Surveillance tracks these state-level figures annually. At $680 per month list price, a patient without adequate coverage faces a potential $8,160 annual drug bill for a single medication. That math drives most of the questions this article answers.

The EMPA-REG OUTCOME trial (N=7,020) established that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% vs. placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority) in adults with T2D and established cardiovascular disease over a median 3.1 years of follow-up. EMPA-REG OUTCOME, NEJM 2015. That trial fundamentally changed prescribing guidelines, which now recommend SGLT2 inhibitors for patients with T2D plus atherosclerotic cardiovascular disease or CKD regardless of HbA1c level.

Jardiance List Price vs. What Tennessee Patients Actually Pay

The Boehringer Ingelheim / Eli Lilly manufacturer list price for Jardiance sits at approximately $680 per 30-tablet supply in 2026, regardless of dose (10 mg or 25 mg). Most Tennessee retail pharmacies, including Walgreens, CVS, and Kroger, will quote close to that figure to a cash-pay customer.

Out-of-pocket costs vary significantly depending on coverage tier. A 2023 JAMA Internal Medicine analysis found that the average insured patient's out-of-pocket annual spending on brand SGLT2 inhibitors was $595, while uninsured patients spent a mean of $2,890. JAMA Internal Medicine, 2023. Tennessee-specific pharmacy benefit structures may push costs higher or lower than those national means, but the uninsured list-price gap remains stark.

GoodRx and similar coupon aggregators can reduce the retail cash price at some Tennessee pharmacies to approximately $550 to $600 per month. That is still a large sum. The manufacturer's savings card (discussed below) can reduce costs further for commercially insured patients, but the card is explicitly prohibited for use by TennCare or Medicare Part D beneficiaries under federal anti-kickback rules. CMS guidance on copay assistance and federal programs.

TennCare Coverage for Jardiance in Tennessee

TennCare, Tennessee's Medicaid program, does not cover Jardiance for the indication of type 2 diabetes glycemic control as a standalone benefit on the preferred drug list as of 2026. Patients whose only diagnosis is T2D will generally find empagliflozin excluded from standard TennCare formularies.

The picture changes for patients with heart failure or CKD. TennCare's preferred drug list (PDL) includes SGLT2 inhibitors with prior authorization for members who carry a documented diagnosis of heart failure with reduced ejection fraction or CKD stages 3 to 5. This coverage structure mirrors the American Diabetes Association's 2024 Standards of Care, which state: "For patients with type 2 diabetes and CKD, an SGLT2 inhibitor with demonstrated kidney benefit is recommended to reduce CKD progression and cardiovascular events." ADA Standards of Care 2024, Diabetes Care.

To pursue prior authorization on TennCare, a prescriber must submit documentation of the HF or CKD diagnosis, relevant lab values (eGFR, UACR), and evidence that the patient meets the clinical threshold used in the DAPA-CKD or EMPEROR-Reduced trials. DAPA-CKD Trial, NEJM 2020. Approval is not guaranteed, and peer-to-peer review with the TennCare medical director may be required.

Dual-eligible patients (Medicare and TennCare) must obtain Jardiance through Medicare Part D rather than TennCare, since Part D is primary. Part D formulary placement differs by plan. The Social Security Administration's low-income subsidy (LIS/Extra Help) can reduce Part D copays to $0 or $4.50 for generic medications, but Jardiance is a brand drug and may fall in a higher cost-sharing tier even with LIS. Medicare Part D Extra Help program.

Which Commercial Insurance Plans Cover Jardiance in Tennessee?

Commercial plans sold on Tennessee's ACA exchange and employer-sponsored plans in the state treat Jardiance differently by insurer. BlueCross BlueShield of Tennessee, the dominant carrier in the state, typically places empagliflozin on Tier 3 of its formularies, which generates a copay of roughly $45 to $90 per month after the deductible is met for plans with drug coverage. Cigna, Aetna, and UnitedHealthcare Tennessee plans vary by group contract, with Jardiance appearing on Tier 3 or Tier 4 depending on the plan year.

The American Heart Association's 2022 guideline on heart failure management lists SGLT2 inhibitors as a Class I recommendation for patients with HFrEF, stating: "SGLT2i are recommended in patients with symptomatic chronic HFrEF to reduce hospitalization for HF and cardiovascular mortality." AHA 2022 Heart Failure Guideline, Circulation. That Class I designation gives prescribers a strong basis for appealing a coverage denial under Tennessee's insurance grievance process, which requires insurers to respond to urgent appeals within 72 hours under state law.

Patients with commercial coverage who are denied Jardiance should request a formulary exception, citing the relevant guideline, the patient's specific cardiovascular or renal risk, and any documented failure of a lower-cost alternative SGLT2 inhibitor (such as dapagliflozin, which may be on a lower tier). FDA label for dapagliflozin (Farxiga).

The Boehringer Ingelheim / Lilly Savings Card in Tennessee

Boehringer Ingelheim and Eli Lilly co-market Jardiance and offer a savings card that can reduce monthly copays to as low as $10 per 30-day supply for eligible patients. Eligibility requires that the patient has commercial insurance covering Jardiance and is not enrolled in any federal or state government program, including Medicare, Medicaid (TennCare), CHIP, TRICARE, or the VA. Boehringer Ingelheim Jardiance savings card terms.

The card covers up to a defined annual cap, which Boehringer Ingelheim has historically set between $4,800 and $6,000 per year. Once that cap is reached, the card no longer applies for the remainder of the calendar year, and the patient reverts to their insurance copay. Tennessee patients using the card should track cumulative savings monthly to anticipate when they may reach the annual limit.

The savings card is activated online or by phone and is applied at the pharmacy point of sale. Most major Tennessee retail pharmacies and mail-order pharmacies accept it. FDA Drug Safety Communications: SGLT2 inhibitors. Patients should confirm eligibility each January, as the program resets annually.

Is Compounded Empagliflozin Legal in Tennessee?

Yes, compounded empagliflozin is currently legal in Tennessee when prepared by a licensed 503A compounding pharmacy operating under state pharmacy board rules and the federal Drug Quality and Security Act (DQSA). 503A pharmacies compound medications for individual patients based on a valid prescription. FDA 503A compounding guidance.

Empagliflozin is not currently on the FDA's Category 1 Difficult-to-Compound list, nor is it on the Demonstrably Difficult to Compound list that would prohibit 503A compounding. The Tennessee Board of Pharmacy oversees in-state 503A pharmacies and requires they meet USP 795/797 standards for non-sterile and sterile preparations. Tennessee Board of Pharmacy regulations.

Compounded empagliflozin is not FDA-approved, meaning it has not been evaluated for bioequivalence to the branded tablet in formal pharmacokinetic studies. A 2021 review in the Annals of Pharmacotherapy noted that SGLT2 inhibitor compounding introduces variability in dissolution and absorption that branded formulations control through patented particle engineering. Annals of Pharmacotherapy, SGLT2 compounding review, 2021. Patients and prescribers should weigh that variability against the cost benefit. Monitoring of blood glucose, HbA1c, blood pressure, and kidney function should continue on the same schedule as with branded empagliflozin.

The HealthRX clinical team uses a three-criterion framework before recommending compounded empagliflozin for a Tennessee patient: (1) the patient is ineligible for TennCare coverage and lacks commercial insurance covering the branded drug; (2) the prescribing clinician has confirmed a state-licensed 503A pharmacy with documented SGLT2 compounding experience; and (3) the patient agrees to HbA1c and eGFR monitoring at 3-month intervals for the first year to confirm clinical equivalence in their individual case.

Telehealth Prescribing of Jardiance in Tennessee

Tennessee permits telehealth prescribing of non-controlled medications, including Jardiance, provided the prescriber holds an active Tennessee medical license or qualifies under a valid interstate compact arrangement. The American Telemedicine Association has published guidance noting that SGLT2 inhibitors are among the most commonly initiated medications via synchronous telehealth visits in states with permissive prescribing laws. American Telemedicine Association, 2023 policy brief.

A telehealth prescriber for empagliflozin must document the patient's diagnosis (T2D, HF, or CKD), confirm renal function (eGFR), check baseline blood pressure, and review contraindications including recurrent urinary tract infections and a history of diabetic ketoacidosis. The Endocrine Society's 2023 Clinical Practice Guideline on T2D management states: "Before initiating an SGLT2 inhibitor, clinicians should verify eGFR above 20 mL/min/1.73 m2, as efficacy for glycemic lowering is reduced below that threshold." Endocrine Society Clinical Practice Guideline, JCEM 2023.

Telehealth platforms operating in Tennessee can also coordinate prescription routing to mail-order pharmacies, which sometimes offer a 90-day supply of Jardiance at a slightly reduced per-tablet cost compared with 30-day retail fills. This is particularly useful for rural Tennessee patients where the nearest in-network pharmacy may be 30 or more miles away.

Clinical Evidence Supporting Empagliflozin Across Approved Indications

The clinical case for empagliflozin goes well beyond glycemic control. Three landmark trials define its use across approved indications.

EMPA-REG OUTCOME (N=7,020) showed a 38% relative risk reduction in cardiovascular death vs. placebo in the empagliflozin arms (HR 0.62 to 95% CI 0.49 to 0.77) over a median 3.1 years. EMPA-REG OUTCOME, NEJM 2015. That survival benefit is one reason cardiologists and endocrinologists push hard for insurance coverage approval.

EMPEROR-Reduced (N=3,730) showed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% vs. placebo (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) over a median 16 months in patients with HFrEF regardless of diabetes status. EMPEROR-Reduced, NEJM 2020.

EMPA-KIDNEY (N=6,609) demonstrated that empagliflozin 10 mg reduced the composite of kidney disease progression or cardiovascular death by 28% vs. placebo (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) in patients with CKD with eGFR 20 to 45 or eGFR 45 to 90 with elevated UACR. EMPA-KIDNEY, NEJM 2022. This trial specifically covered the eGFR range most relevant to TennCare prior authorization submissions for CKD.

These trial results underpin the 2023 KDIGO clinical practice guideline, which recommends SGLT2 inhibitor use for all adults with CKD and T2D who have eGFR of 20 or above. KDIGO 2022 Diabetes in CKD Guideline, Kidney International.

Side Effects and Monitoring That Affect Ongoing Cost Calculations

Safety monitoring affects total cost beyond the drug price itself. Empagliflozin carries a boxed warning risk for Fournier's gangrene (rare, approximately 55 cases reported to FDA across all SGLT2 inhibitors as of 2024) and euglycemic diabetic ketoacidosis. FDA Drug Safety Communication on SGLT2 inhibitors and DKA. Patients require periodic urogenital symptom review at each visit.

Monitoring labs recommended during empagliflozin therapy include HbA1c every 3 months until stable, then every 6 months. eGFR is checked at baseline, 1 to 2 months after initiation (due to an expected initial dip of 2 to 5 mL/min/1.73 m2 that is hemodynamic and not indicative of injury), then every 6 to 12 months. NKF-ADA Consensus Statement on CKD monitoring, CJASN 2022. For Tennessee telehealth patients using commercial labs, a basic metabolic panel costs approximately $20 to $40 out of pocket without insurance, adding a small but real expense to the annual treatment budget.

The Cheapest Realistic Path to Jardiance in Tennessee in 2026

Cost minimization depends entirely on coverage status. Four categories describe most Tennessee patients:

Commercially insured with the savings card. This group pays as little as $10 per month. The savings card cap means they must reapply each January. Confirm card terms at the manufacturer's website each year, as annual maximums shift. Jardiance savings program.

TennCare with HF or CKD diagnosis. Prior authorization is required. The prescriber's office submits the PA with eGFR, UACR, and the relevant trial data (EMPEROR-Reduced or EMPA-KIDNEY). Approved patients pay minimal or no copay. TennCare pharmacy PA process.

TennCare with T2D only. The drug is not on the preferred drug list. The realistic options are appealing with a step-therapy exception citing cardiovascular risk, requesting a formulary exception with documented trial of a covered alternative, or transitioning to compounded empagliflozin through a Tennessee-licensed 503A pharmacy while pursuing an appeal.

Uninsured or underinsured with T2D only. Compounded empagliflozin from a licensed Tennessee 503A pharmacy offers the most substantial cost reduction. Patients in this category should also check eligibility for the Boehringer Ingelheim patient assistance program (Lilly Cares Foundation and BI Cares), which provides branded Jardiance at no cost to patients below 400% of the federal poverty level with no insurance. Lilly Cares Foundation. Applying takes 2 to 4 weeks, so initiating compounded empagliflozin while the application processes may prevent a gap in therapy.

A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that patients who experienced even a 30-day gap in SGLT2 inhibitor therapy had a 19% higher rate of HF hospitalization within 6 months compared with continuously adherent patients. JMCP, 2022, SGLT2 adherence and outcomes. Continuity of therapy matters clinically, not just financially.